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Acute heart failure syndromes (AHFS) have emerged as a leading public health problem worldwide, accounting for a
substantial number of hospitalizations and a high utilization of resources. Although in-hospital mortality rates are rela-
tively low, patients with AHFS have very high early after-discharge mortality and rehospitalization rates. The majority
of patients admitted with AHFS have coronary artery disease (CAD), which independently has an adverse impact on
prognosis. The initial in-hospital and after-discharge management of AHFS may be dependent on clinical presenta-
tion: AHFS in patients with underlying CAD or acute coronary syndromes (ACS) complicated by heart failure. In addi-
tion, the extent and severity of CAD and the presence of ischemia and/or stunned/hibernating myocardium should be
assessed for optimal management. Although the overall management of AHFS with CAD may be similar to that in
patients with ACS complicated by heart failure, for which specific guidelines exist, management of the former is less
well defined. Prospective studies of the assessment and treatment of CAD in patients with AHFS are urgently
needed. (J Am Coll Cardiol 2009;53:254–63) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.072l
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acute heart failure syndromes (AHFS) can be defined as a
apid or gradual change in signs and symptoms in patients
ith chronic heart failure (HF) or new-onset HF that
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January 20, 2009:254–63 Acute HF and Coronary Diseases high as 15% and 35% at 30 days and 1 year, respectively,
n patients already receiving pharmacologic therapy
angiotensin-converting enzyme inhibitors/angiotensin re-
eptor blockers and beta-blockers) (4,5).
AHFS represent a heterogeneous group of patients in
erms of their clinical presentation, pathophysiology, prog-
osis, and therapeutic options (1). The majority of patients
resenting with AHFS have coronary artery disease (CAD).
hese patients may present in 1 of 2 ways: acute coronary
yndromes (ACS) complicated by HF or AHFS with
nderlying CAD. The role of CAD in AHFS has not been
ell studied in clinical trials. Therapies that have shown to
ignificantly improve morbidity and mortality, including
harmacologic and device therapies, have been studied in
atients with chronic ambulatory HF with or without
AD. Given the severity of hemodynamic and neurohor-
onal activation in acute versus chronic HF, assessing for
he presence, extent, and severity of CAD in patients with
HFS may have important therapeutic implications for the
nitial (emergency department), in-hospital, and after-
ischarge management.
The cornerstone of the evaluation of CAD in ACS is
oronary angiography. The evaluation of CAD in AHFS
ith coronary angiography, often in conjunction with non-
nvasive functional imaging to detect ischemic or dysfunc-
ional but viable myocardium, may represent an emerging
pproach to the assessment and management of AHFS
atients. Current practice guidelines (6–11) have consider-
ble overlap with respect to patients with HF. Although
hese guidelines provide recommendations on the use of
oronary angiography for more appropriate use of pharma-
ological and/or myocardial revascularization in patients
ith chronic HF, they do not specifically address the timing
nd selection for these measures in patients with AHFS and
AD (6–11).
This document represents a consensus summary of dis-
ussions that occurred during the fourth International Acute
eart Failure Syndromes Working Group meeting in
hicago, Illinois, in April 2007.
HFS
pidemiology. AHFS account for more than 1 million
ospitalizations per year in the U.S. and a similar number in
urope (12). They are the most common cardiovascular
ause of hospitalization in the U.S., with a median stay of 3
o 4 days (1). AHFS is also the most common overall cause
f hospitalization in adults 65 years and older, accounting
or more than 5% to 10% of all admissions (13). Approxi-
ately 80% of patients hospitalized with AHFS carry a
revious diagnosis of HF. In 15% of patients the diagnosis
f HF is new, and the remaining 5% are admitted with
dvanced or refractory HF (1). The highest relative risk for
ortality occurs within 30 to 60 days after discharge (1,2).
he total direct and indirect health care costs of HF in the
.S. for 2006 have been estimated to be $29.6 billion, with ahe great majority of costs attrib-
table to hospitalization (14). As
he burden of AHFS increases
ith the aging population, the
mportance of evidence-based
trategies to prevent HF exacer-
ations, decrease hospitaliza-
ions, contain costs, and improve
utcomes has become an urgent
ublic health issue.
rognosis. The long-term prog-
osis for chronic HF patients
ith left ventricular (LV) systolic
ysfunction has improved over
he past 10 to 20 years, largely
ecause of improved pharmaco-
ogical therapy, advanced cardio-
ascular surgical and interven-
ional techniques, and the use of
mplantable cardiac-defibrillators and cardiac resynchroni-
ation therapy (15,16). Despite these advances, hospitaliza-
ion for HF is one of the most important predictors for
ehospitalization and mortality (2–5). In several recent large
egistries (17–19), AHFS had a 4% to 7% in-hospital
ortality rate. Survivors of hospitalization with AHFS have
n early after-discharge mortality as high as 10% to 15% and
ehospitalization rates of 30% at 60 to 90 days. One-year
ortality rates in community cohorts and registries have
anged from 30% to 40% (4,5). Randomized controlled
rials investigating the role of novel intravenous vasoactive
ompounds and the routine use of pulmonary artery cathe-
ers in the management of AHFS have failed to demon-
trate improved survival or decreased length of hospitaliza-
ion (20–25). In addition, serious concerns regarding the
afety of intravenous vasoactive compounds in the setting of
HFS, especially in those patients with pre-existing CAD,
ave been raised (22,23,26). The traditional targets for
herapy in AHFS are congestion and/or low cardiac output.
lthough interventions that improve hemodynamics are
mportant for the alleviation of the signs and symptoms of
F, they may not prevent myocardial or renal injuries,
hich are often present in AHFS. As a consequence, these
nterventions may not only be ineffective in improving
linical outcomes but may even be deleterious (26–28).
entricular function. Although the majority of trials in
HFS conducted to date (19,29–35) studied patients with
educed systolic function, relatively preserved systolic function
s present in approximately one-half of all patients hospitalized
ith AHFS. Approximately 60% of these patients have doc-
mented CAD (32). Over the past 20 years, the relative
roportion of patients with AHFS and preserved systolic
unction has steadily risen relative to those with LV systolic
ysfunction (29). This rise has corresponded with increased
ates of CAD, hypertension, diabetes, and atrial fibrillation
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AHFS  acute heart failure
syndrome(s)
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CTA  computed
tomography angiography
HF  heart failure
LV  left ventricular
MI  myocardial infarction
MRI  magnetic resonance
imagingmong patients with AHFS (36). Multiple registries have
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Acute HF and Coronary Disease January 20, 2009:254–63emonstrated that the risk of early death and long-term risk of
eath or rehospitalization in AHFS is similar for patients with
reserved systolic function and LV systolic dysfunction (29,32–
4). In the OPTIMIZE-HF (Organized Program to Initiate
ifesaving Treatment in Hospitalized Patients with Heart
ailure) registry (30), the risk of in-hospital death in patients
ith AHFS and preserved systolic function was slightly lower
han in those with AHFS and LV systolic dysfunction (2.9%
s. 3.9%). However, among survivors of the index hospitaliza-
ion, the risk of death (10%) and rehospitalization (30%) in
he first 60 to 90 days after hospital discharge was the same in
he 2 groups (30). These patients, however, are more likely to
ie from other cardiac comorbidities, including CAD, rather
han HF (37,38).
HFS and CAD
ospitalization. Coronary artery disease has emerged as
he dominant etiologic factor in patients with HF. Pooling
ata from 24 multicenter trials of chronic HF over the past
0 years with 43,000 patients (1,36) revealed that 62%
arried a diagnosis of CAD. This number is an underesti-
ation of the prevalence of CAD in this population, as in
linical practice and in most studies there is no systemic
ssessment of coronary artery anatomy. Patients hospital-
zed with AHFS have a worse prognosis when they also
arry a diagnosis of CAD (39). Long-term survival in
atients with HF is directly related to the angiographic
urden of CAD, although this observation may reflect only
he extent of CAD in the epicardial vessels (40,41). Survi-
ors of acute myocardial infarction (MI) not complicated by
F have a relatively high incidence of subsequent HF
ospitalization, which is associated with significantly in-
reased mortality (42).
In a study of 136 patients younger than 75 years of age
ospitalized with incident HF, Fox et al. (43) combined
linical, angiographic, and myocardial perfusion imaging
ata to determine that CAD was the primary etiology in at
east 52% of cases. Of note, in this study, 67% of patients
ho underwent angiography had anatomically significant
AD (defined as50% luminal stenosis), identifying CAD
s a therapeutic target in AHFS even when it was not the
rimary etiologic factor. From the OPTIMIZE-HF registry
f AHFS patients, in which less than one-half had known
AD, Fonarow et al. (44) identified ischemia as the primary
recipitant for hospitalization in 15% of patients. These
atients had significantly worse in-hospital and 60- to 90-day
fter-discharge mortality. Although these data indicate that
AD may cause or precipitate AHFS, the contribution of
AD to clinical decompensation can be difficult to determine
hen multiple comorbid conditions are present.
fter-discharge events. There is no single explanation for
he high mortality and rehospitalization rates in patients
ho survive hospitalization for AHFS. It is possible that
AD is an important contributor to this high after-
ischarge event rate. An autopsy study of 180 patients with Anown ischemic cardiomyopathy (45) revealed that acute
I was responsible for 57% of the deaths. This study
evealed that many deaths due to acute MI in patients with
F were misclassified as due to progressive HF or arrhyth-
ias. In the ATLAS (Assessment of Treatment with
isinopril and Survival) study (46), 54% of patients with
hronic HF and CAD who died suddenly had autopsy
vidence of acute MI.
In a group of patients with HF and LV systolic dysfunc-
ion, 25% of repeat hospitalizations were attributed to ACS
47). Approximately 10% of patients subsequently hospital-
zed for ACS were originally classified as nonischemic. The
n-hospital mortality rate in this group was 36%. These data
uggest that patients with AHFS can be mislabeled as
onischemic or that CAD may either develop or progress in
atients with nonischemic cardiomyopathies (48).
athophysiology: AHFS and CAD
he majority of patients with AHFS and CAD are not
ospitalized or diagnosed with ACS. There are, however,
onsiderable similarities between non-ACS AHFS patients
nd ACS patients complicated by HF (Table 1). In contrast
ith ACS complicated by HF, where myocardial injury is
he principal cause for HF, the myocardial injury in AHFS
n patients with underlying CAD may be related to wors-
ning HF. The injury may be the result of marked hemo-
ynamic and neurohormonal abnormalities known to occur
n the setting of AHFS but less likely to be present in
hronic HF. In AHFS, the high LV diastolic pressure often
esults in subendocardial ischemia, which is associated with
urther activation of neurohormones. This activation can
ncrease cardiac contractility and reduce coronary perfusion
hrough endothelial dysfunction. In addition, patients with
haracteristics of Patients With AHFS andAD Versu Patients With ACS Complicated by HF
Table 1 Characteristics of Patients With AHFS andCAD Versus Patients With ACS Complicated by HF
AHFS and CAD ACS Complicated by HF
Dyspnea Common Common
Chest discomfort Uncommon Common
Prior HF Common Uncommon
BNP/N-terminal proBNP Elevated Elevated
Troponin Normal or elevated* Usually elevated
Left ventricular systolic
function
Normal or
depressed
Normal or depressed
Diagnostic testing for CAD†
(ischemia/viability/
angiography)
Uncommon Standard (per guidelines)
Myocardial
revascularization
Uncommon† Standard (per guidelines)
Secondary prevention for
CAD
Underused Standard (per guidelines)
In-hospital mortality Relatively low Relatively high
Early after-discharge death
or rehospitalization
High High
Typically low-level elevation. †During index hospitalization.
ACS acute coronary syndrome; AHFS acute heart failure syndrome; BNP B-type natriuretic
eptide; CAD  coronary artery disease; HF  heart failure.HFS and CAD often have hibernating or stunned myo-
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January 20, 2009:254–63 Acute HF and Coronary Diseaseardium (28). Together, all of these factors may result in
yocardial injury (1).
Hypotension in AHFS patients is associated with increased
ortality (49). Coronary perfusion may be further impaired in
HFS in the setting of low systemic blood pressure. In this
etting, the autoregulation between coronary artery perfusion
ressure and coronary vasoactive tone may be lost or impaired
n patients with obstructive epicardial CAD (28). This may
xplain why patients with AHFS and CAD frequently have
roponin elevation. These troponin elevations most likely
epresent myocardial injury and are associated with worse
utcomes (50–55). In the PRESERVED-HF (Pilot Ran-
omized Study of Nesiritide Versus Dobutamine in Heart
ailure) trial, 74% of non-ACS patients with AHFS and
nown CAD had low-level troponin elevation at the time of
ospital admission (54). Of the 26% who did not initially have
roponin elevation, 42% had troponin elevation within 72 h
for a total of 85% of all patients within 72 h of admission).
ata from ADHERE (Acute Decompensated Heart Failure
ational Registry) (55) indicate that patients admitted with
HFS not thought to have ACS but with troponin elevations
hat exceed the laboratory threshold for acute MI have signif-
cantly higher in-hospital mortality (8.0% vs. 2.7%, p 0.001).
It appears that a history of myocardial revascularization in
atients with AHFS is associated with improved outcomes
53,56). The lack of typical angina despite myocardial injury
n AHFS patients may be due to the predominance of
espiratory symptoms; the high incidence of diabetes; and
he use of medications, including nitrates and beta-blockers,
hat may blunt angina. When it does occur, chest pain in
HFS patients is often a sign of myocardial injury. In one
tudy (57), 32% of patients with chronic HF presenting to
he emergency department with chest pain were diagnosed
ith ACS.
athophysiology: ACS Complicated by HF
pproximately 10% to 20% of patients with ACS have
oncomitant HF, and up to 10% of ACS patients develop
F during hospitalization (58–63). In the EuroHeart
urvey II on HF (64), 37% of patients had de novo HF,
2% of which was attributable to ACS. Patients with ACS
nd ST-segment elevation typically have high levels of
ardiac biomarker elevation, corresponding to high levels of
yocardial injury. Of ACS patients with HF but without
T-segment elevation, more than two-thirds have signifi-
ant cardiac enzyme elevation (troponin3 times the upper
imit of normal), a proportion similar to those presenting
ithout HF (52). The majority of these patients do not have
history of HF and have preserved systolic function (58,60).
he short-term risk of adverse clinical outcomes in patients
ith ACS complicated by HF is directly proportional to the
evel of troponin elevation (65).
Patients with ACS complicated by HF have markedly
ncreased short- and long-term mortality rates compared
ith those without HF (58–60,66–73). Patients who de- belop HF after presentation have even higher mortality than
hose presenting with ACS and HF (59,63). The prognosis
f ACS complicated by HF is directly related to the degree
f HF as measured by the Killip classification (59,61,63).
ompared with those with Killip class I HF, patients with
n ACS in Killip class II or III HF are 4 times more likely
o die during the index hospitalization, whereas those with
ardiogenic shock (class IV) have a 10-fold higher mortality
60,63). Furthermore, among ACS patients who recover
rom transient HF, the majority develop recurrent HF (42).
ssessment of CAD in AHFS
urrently, there are no consensus statements or practice
uidelines on the most appropriate timing and methods to
etect or reassess CAD in patients with AHFS. Most
tudies have used clinical criteria, including a history of MI,
ngina, or myocardial revascularization, or the results of
xercise testing and/or noninvasive imaging to determine
hich patients with AHFS have CAD. This approach may
ontribute to the underdiagnosis of CAD and its severity in
his population.
Electrocardiography and echocardiography are the
ost common cardiac diagnostic tests obtained in pa-
ients with AHFS (19). Patients with LV systolic dys-
unction and electrocardiographic Q waves usually have
ignificant CAD (74). However, most patients with HF
nd CAD do not have Q waves, whereas those with
onischemic cardiomyopathies can have Q waves (74).
imilarly, segmental wall motions identified by echocar-
iography are predictive of CAD, but not its extent and
everity (74,75).
oronary Angiography
oronary angiography is the gold standard for the diagnosis
nd reassessment of CAD against which all other modalities
re compared (41). In patients with HF, the long-term
rognosis is directly related to the angiographic extent and
everity of CAD (40,41). This has been demonstrated in
F patients with LV systolic dysfunction and preserved
ystolic function (76). A clinical strategy in the evaluation of
HFS that does not assess for the presence, extent, and
everity of CAD may grossly underestimate its prevalence.
espite the existing guidelines and the high incidence of
AD in patients with AHFS, angiography is used infre-
uently for the assessment or reassessment of CAD (6). In
large AHFS registries, coronary angiography was per-
ormed in only 9% to 16% of patients during the index
ospitalization (1,19). Similarly low rates of angiography
ave been observed in a community-practice setting for
atients with newly diagnosed AHFS (77). Patients with
CS complicated by HF are less likely to undergo coronary
ngiography and revascularization and to receive pharma-
ological therapy for CAD than ACS patients without HF
62,63,73,78,79). In the OPTIMIZE-HF registry, it has
een preliminarily reported (80) that performance of coro-
n
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Acute HF and Coronary Disease January 20, 2009:254–63ary angiography during the index hospitalization for
HFS was associated with an increased utilization of
spirin, statins, and myocardial revascularization and a
educed risk of death at 60 to 90 days after discharge. This
aises the hypothesis that the knowledge of the extent and
everity of CAD in AHFS patients will have an important
ole in treatment decisions.
Multidetector coronary computed tomography angiography
CTA) has been shown to be highly accurate to determine the
resence or absence of CAD in patients with HF (81).
owever, when CAD is present, the ability of CTA to define
ts extent and severity is hampered by unseen segments and
rtifacts caused by motion and calcium (82). This role of
oronary CTA in this population may be an important focus of
uture investigations, but currently cannot be recommended in
ieu of coronary angiography at this time.
yocardial Ischemia
n patients with AHFS and evidence of ischemia, the
iagnosis of obstructive CAD by angiography should lead to
he consideration of early myocardial revascularization and
ggressive medical therapy with antiplatelet agents and
tatins in addition to beta-blockers and ACE inhibitors/
ngiotensin receptor blockers. In the absence of clinical
igns of ischemia, additional testing may be needed to guide
herapeutic choices (83). Dobutamine stress echocardiogra-
hy detects ischemia through the induction of new or
xaggerated LV wall motion abnormalities during stepwise
nfusion of dobutamine. Nuclear perfusion imaging with
ingle-photon emission computed tomography uses intra-
enously delivered radioisotopes (thallium-201 chloride or
echnetium-99m labeled tracers); regions with defects fol-
owing stress that normalize at rest are indicative of isch-
mia. More recently, positron emission tomography has also
een used to assess ischemia, employing tracers such as
ubidium-82, N13-ammonia, or O15-labeled water. Vaso-
ilator stress magnetic resonance imaging (MRI) is a newer
oninvasive stress imaging modality that has not yet been
tudied in HF patients for the assessment of ischemia (84).
yocardial Viability
he presence of viable but dysfunctional myocardium can be
sed to predict a favorable response to myocardial revascu-
arization and pharmacological therapy (85–87). Left ven-
ricular systolic dysfunction can be secondary to repetitive
tunning or hibernation. In this setting, stunning is defined
s reversible LV dysfunction attributable to repetitive epi-
odes of ischemia, whereas hibernating myocardium is
efined as reversible LV dysfunction caused by chronic
ypoperfusion (88). Up to 50% of patients with CAD and
hronic LV dysfunction have significant areas of dysfunc-
ional but viable myocardium (89). Hibernating myocar-
ium is associated with global alterations in LV volumes
nd shape, not just impairment of underperfused ventricular
egments (88). This explains why myocardial revasculariza- lion of hibernating territories can promote reverse remod-
ling globally (90).
The identification of viable myocardium is based on detec-
ion of its characteristics, which include intact perfusion, cell
embrane integrity, intact mitochondria, preserved glucose
etabolism and contractile reserve (85,88,91,92). Intact per-
usion, cell membrane integrity, and intact mitochondria can
e evaluated with single-photon emission computed tomogra-
hy imaging using thallium-201 chloride and/or technetium-
9m labeled tracers. Preserved glucose metabolism can be
ssessed by positron emission tomography using F18-
uorodeoxyglucose. Contractile reserve can be unmasked by
nfusion of low-dose dobutamine during echocardiography.
he use of these techniques has been associated with improved
urvival in patients with chronic HF and significant viability
ho underwent myocardial revascularization (85,88,91,92).
Cardiac MRI is another technique to assess myocardial
iability (93,94). Resting cine MRI can be used to assess LV
nd-diastolic wall thickness. It has been shown that an
nd-diastolic wall thickness 5 to 6 mm is a marker of
ransmural MI and virtually excludes the presence of viable
yocardium. In dysfunctional myocardium with preserved
nd-diastolic wall thickness (6 mm), detection of contrac-
ile reserve during low-dose dobutamine infusion confirms
he presence of viable myocardium. Gadolinium-based con-
rast agents have been used to detect nonviable myocardium,
s these agents accumulate selectively in areas of scar tissue.
t should be noted that this technique is extremely sensitive
o detect scar tissue (with very high spatial resolution), but
he absence of scar tissue does not permit discrimination
etween normal tissue and hibernating or stunned myocar-
ium (93).
reatment of CAD in AHFS
harmacologic therapy. The presence of CAD in patients
ith AHFS may have a profound impact on treatment.
onsidering the overlap in pathophysiology, including in-
reased platelet reactivity, myocardial ischemia and injury,
herapies for AHFS andAD Ver us ACS Complicated by HF
Table 2 Therapies for AHFS andCAD Versus ACS Complicated by HF
AHFS and CAD
ACS Complicated
by HF
Immediate therapies
Nitrates Yes Yes
Antiplatelet agents Yes Yes
Anticoagulation No Yes
Inotropes Avoid if possible Avoid if possible
Statins Yes Yes
Renin-angiotensin system modulation
ACE-I or ARB Yes Yes
Aldosterone blockade (if LVSD) Yes Yes
Beta-blockers Yes Yes
Early angiography/revascularization Yes* Yes*
If jeopardized myocardium present (ischemia or viability).
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; LVSD 
eft ventricular systolic dysfunction; other abbreviations as in Table 1.
i
t
a
m
A
t
C
i
d
p
h
n
m
(
b
A
n
h
a
n
C
l
m
p
d
d
w
i
O
t
F
n
m
m
c
a
i
c
o
f
a
m
(
p
a
t
t
d
m
s
H
b
w
r
t
o
s
M
C
c
b
i
a
c
m
L
w
p
h
s
e
p
w
(
i
d
i
r
H
l
L
t
a
u
n
t
s
i
h
r
p
A
r
e
w
w
p
a
r
m
w
r
d
c
n
259JACC Vol. 53, No. 3, 2009 Flaherty et al.
January 20, 2009:254–63 Acute HF and Coronary Diseasempaired coronary perfusion, and elevated LV filling pressure,
he treatment approach for AHFS with CAD can be modeled
fter the standard approach for ACS (Tables 1 and 2). This
ay include the early administration of antiplatelet therapy in
HFS patients with known CAD or suspected ischemia (95).
The immediate management of AHFS usually occurs in
he emergency department. In patients with underlying
AD who are not hypotensive, nitrates may be the ideal
nitial agents. Nitrates provide rapid reduction of myocar-
ial ischemia and can improve coronary perfusion. In
atients with severe pulmonary edema, the combination of
igh-dose nitrates and low-dose diuretics (vs. low-dose
itrates and high-dose diuretics) led to a decreased need for
echanical ventilation and significantly lower rates of MI
96). A regimen consisting of lower doses of diuretics has
een proposed as a method of preserving renal function in
HFS. In a large AHFS registry, the use of intravenous
itroglycerin or nesiritide was associated with lower in-
ospital mortality compared with treatment with dobut-
mine or milrinone (97). However, compared to intravenous
esiritide in AHFS patients (60% with documented
AD), intravenous nitroglycerin has been associated with
ess deterioration of renal function and a trend toward less
ortality at 30 days (23,98,99).
Inotropes may be particularly harmful when used in
atients with AHFS and CAD. Experimentally, the use of
obutamine in a model of HF with hibernating myocar-
ium led to increased myocardial necrosis (27). Patients
ith AHFS and troponin elevation have significantly higher
n-hospital mortality when inotropes are used (55). In the
PTIME-CHF (Outcomes of a Prospective Trial of In-
ravenous Milrinone for Exacerbations of Chronic Heart
ailure) trial (26), the phosphodiesterase inhibitor milri-
one was assessed during AHFS. In patients with CAD,
ilrinone was associated with increased after-discharge
ortality compared with placebo. In general, a decrease in
oronary perfusion as a result of a decrease in blood pressure
nd/or an increase in heart rate, often resulting from
notropes with vasodilator properties or inotropes used in
onjunction with vasodilators, may be particularly deleteri-
us in patients with AHFS and CAD (26,100).
The pre-discharge initiation of optimal medical therapy
or HF, including beta-blockers and ACE inhibitors or
ngiotensin receptor blockers, is associated with improved
edication adherence and an early survival advantage
80,101–103). The continuation of beta-blocker therapy in
atients hospitalized with AHFS is associated with lower
fter-discharge mortality risk (104). Also, the addition of
he aldosterone blocker eplerenone to optimal medical
herapy in ACS patients complicated by HF and LV systolic
ysfunction was shown (105) to significantly reduce overall
ortality, sudden cardiac death, and rehospitalization.
Medical regimens for CAD can differ according to HF
tatus. Acute coronary syndrome patients complicated by
F are less likely to receive antiplatelet agents, beta-lockers, ACE inhibitors, or statins than are ACS patients dithout HF (42,58,60,62,63). In the OPTIMIZE-HF
egistry (106), only 14,904 of 38,066 (39.2%) AHFS pa-
ients with documented CAD, hyperlipidemia, diabetes, or
ther atherosclerotic vascular disease were treated with
tatins.
yocardial revascularization. The American College of
ardiology/American Heart Association and European So-
iety of Cardiology practice guidelines for coronary artery
ypass graft (CABG) surgery and percutaneous coronary
ntervention do not specifically address patients with CAD
nd AHFS (9–11). Revascularization may improve out-
omes in patient with HF and dysfunctional but viable
yocardium. In a meta-analysis of 3,000 patients with
V systolic dysfunction, revascularization was associated
ith markedly decreased yearly mortality (3.2% vs. 16.0%,
 0.0001) if viability was present (85). In patients without
ibernating myocardium, revascularization did not improve
urvival. Recently, a retrospective observational study (107)
xamined the role of myocardial revascularization in4,000
atients with chronic HF. At 1 year, patients who under-
ent revascularization had substantially reduced mortality
11.8% vs. 21.6%, hazard ratio: 0.52, 95% confidence
nterval: 0.47 to 0.58). The survival curves continued to
iverge through 7 years of follow-up. This data is limited by
ts restrospective nature. However, the ongoing prospective
andomized STICH (Surgical Treatment for Ischemic
eart Failure) trial may help elucidate the role of revascu-
arization in chronic heart failure patients with CAD and
V systolic dysfunction (36).
Revascularization is rarely performed during hospitaliza-
ion for AHFS. In 3 large AHFS registries that included
pproximately 170,000 patients, only 2% to 4% of patients
nderwent coronary artery bypass graft surgery or percuta-
eous coronary intervention (1,14,108). Outcomes in pa-
ients with AHFS in the setting of ACS are improved by a
trategy of early revascularization (109). Patients hospital-
zed with AHFS have improved early survival if they have a
istory of myocardial revascularization, although this is a
etrospective finding (53,56). These data generate the hy-
othesis that early revascularization will be beneficial in
HFS patients with ischemia due to CAD. This hypothesis
emains to be tested in a prospective randomized study of
arly myocardial revascularization in non-ACS patients
ith AHFS and CAD.
A strategy of early angiography and revascularization,
here appropriate, in AHFS must take into account the
otential risks and costs. The risk of vascular complications
nd contrast-induced nephropathy has steadily declined in
ecent years owing to technical and preventative advance-
ents (110,111). The cost-effectiveness of such a strategy
ill probably depend most on its impact, if any, on
ehospitalization rates. The use of coronary angiography
uring hospitalization for AHFS is associated with a de-
reased risk of early rehospitalization (80), but this also
eeds to be prospectively studied. A formal strategy to
etect or reassess the extent and severity of CAD in patients
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Acute HF and Coronary Disease January 20, 2009:254–63ith AHFS may improve the implementation of evidence-
ased therapies that can improve clinical outcomes (Fig. 1).
onclusions
HFS have emerged as a leading public health problem
orldwide, accounting for a substantial number of hospi-
alizations and a high utilization of resources. A significant
umber of patients admitted with AHFS have CAD and
an be divided into those who present with or without ACS.
oth groups have high early after-discharge mortality and
ehospitalization rates. Knowledge of the extent and severity
f CAD and the presence of ischemic and/or stunned/
ibernating myocardium may influence the initial and
n-hospital management of these patients. Although specific
uidelines exist for patients with ACS complicated by HF,
rospective studies of the assessment and treatment of CAD
n the setting of acute HF are urgently needed.
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